Company & Sponsor Intelligence

Yonsei University

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →
Indexed trials3
Recruiting0
Completed3
Countries1

Therapeutic footprint

epilepsysleep_disordersstroke

Indexed studies

NCT06339853Study of Efficacy of Digital Cognitive Behavioral Therapy With Wearable Device for Insomnia
sleep_disorders · South Korea
NA
NCT03198949A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)
epilepsy · South Korea
PHASE2
NCT02964052Selection Criteria in Endovascular Thrombectomy and Thrombolytic Therapy (SECRET) Study: Development of Patient Selection Criteria Using CT Images and Accompanying Diseases for Efficient Intravenous Thrombolytic and Intra-arterial Recanalization Therapy in Acute Ischemic Stroke
stroke · South Korea
COMPLETED

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →